GlobeNewswire

Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
23/03/2026
– Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC – – Combined feedback from [...]
Tempest Therapeutics Announces Up To $6 Million Private Placement
23/03/2026
$2 million upfront with up to approximately $4 million of potential aggregate gross proceeds upon the exercise in full of warrants BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering
23/03/2026
CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
23/03/2026
NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
23/03/2026
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology represents [...]
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
23/03/2026
XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class multi-specific, [...]
Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l’essai de Phase 3 VALOR
23/03/2026
Le candidat vaccin PF-07307405 (LB6V) a démontré une efficacité de plus de 70 % dans la prévention de la maladie de Lyme chez les personnes âgées de cinq ans et plus. Le candidat vaccin a été bien toléré, sans problème [...]
Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas Breakthroughs Creating New Spider Silk Transgenics
23/03/2026
ANN ARBOR, Mich., March 23, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a significant [...]
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
23/03/2026
MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a [...]
Tessera Therapeutics Receives Grant to Advance In Vivo Gene Writing Approaches Towards a Potential Human Immunodeficiency Virus (HIV) Cure
23/03/2026
Funding from the Gates Foundation supports development of multiple in vivo Gene Writing strategies aimed at enabling a scalable cure for HIV SOMERVILLE, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- SOMERVILLE, Mass., March [...]
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
23/03/2026
-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial Revenue in 24 Months [...]
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
23/03/2026
Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026 Cash, cash equivalents and short-term investments of approximately $98 [...]
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
23/03/2026
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated [...]
EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
23/03/2026
Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia SAN JOSE, Calif., March 23, 2026 (GLOBE [...]
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
23/03/2026
SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board POMPANO BEACH, Fla., March 23, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies (OTC: BSEM), a leading MedTech [...]
Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building
23/03/2026
VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to announce that it will be opening its [...]
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
23/03/2026
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients maintained vIGA 0/1 [...]
Philips convenes the Annual General Meeting of Shareholders 2026
23/03/2026
March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published [...]
Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer
23/03/2026
BASEL, Switzerland, March 23, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of Thaminda [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum